alizapride

structure given in first source

Also Known As:

Litican; MS 5080; MS-5080; N-((1-allyl-2-pyrrolidinyl)methyl)-6-methoxy-1H-benzotriazole-5-carboxamide; N-((allyl-1-pyrrolidinyl-2)-methyl)methoxy-2-azimido-4,5-benzamide; N-(1-allyl-2-pyrrolidinylmethyl)-6-methoxy-1H-benzotriazole-5-carboxamide hydrochloride; Plitican; Vergentan; alizapride hydrochloride

Networked: 67 relevant articles (13 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - alizapride: 67

Experts

1.	Horta, M L: 2 articles (06/2006 - 08/2003)
2.	Bihin, Benoît: 1 article (01/2020)
3.	Charles, Océane: 1 article (01/2020)
4.	Colsoul, Marie-Lise: 1 article (01/2020)
5.	Galanti, Laurence: 1 article (01/2020)
6.	Goderniaux, Nicolas: 1 article (01/2020)
7.	Hecq, Jean-Daniel: 1 article (01/2020)
8.	Jamart, Jacques: 1 article (01/2020)
9.	Soumoy, Laura: 1 article (01/2020)
10.	Devroe, Sarah: 1 article (02/2016)

Related Diseases

1.	Vomiting 12/01/1990 - "This study confirms the good risk/benefit ratio of alizapride in the treatment of emesis in infants and children." 02/11/1982 - "[A study of the effectiveness of alizapride against emesis in children (author's transl)]." 02/01/1990 - "[The value of alizapride in the treatment of vomiting in infants and children]." 02/01/1988 - "The incidence of vomiting in the placebo-group was twice as high as in the alizapride-groups. " 01/01/1988 - "In the alizapride group there was less retching or emesis than in the placebo-group and the difference was statistically significant. "
2.	Nausea 04/14/1983 - "The incidence of severe nausea was reduced from 50% to 24% on day 3. The percentage of patients without vomiting was raised to 77% until day 5. These results are in line with those of other clinical studies on Alizapride." 01/01/1988 - "We conclude that alizapride is more active than placebo when combined with DXM for DDP-induced emesis in patients at high risk of severe nausea and vomiting. " 06/03/1982 - "Our results suggest that alizapride, in a dose of 800 or 900 mg, significantly alleviates nausea and emesis. " 04/15/1986 - "Nabilone was superior to alizapride in giving complete relief from nausea (medians, 65% vs 30%; p less than 0.01), and was more effective in shortening the duration of nausea (medians, 1.3 h vs 5.1 h; p less than 0.01); however, it caused more adverse effects. " 01/01/1989 - "A study about alizapride in out patients with nausea and vomiting during infusional antiblastic chemotherapy."
3.	Neoplasms (Cancer) 12/01/1987 - "Fifty patients with various urological malignancies were registered into this study, which were distributed to the aliquot number with a respective dose schedule of 2, 3, 4 and 5 mg/kg body weight of MS-5080. " 09/08/1983 - "[Phase I study of alizapride in cancer patients treated with cisplatin]." 02/11/1982 - "[A double-blind crossover trial of alizapride versus placebo regarding effectiveness against nausea and emesis induced by cancer chemotherapeutic agents (author's transl)]." 02/11/1982 - "[A double-blind study of alizapride in nausea and emesis induced by cancer chemotherapeutic agents (author's transl)]." 10/01/1990 - "We made a study on patients suffering from neoplasias treated with cisplatinum to compare antiemetic efficacy of alizapride or associated to dexamethasone. "
4.	Postoperative Nausea and Vomiting (PONV) 02/01/2016 - "Due to the lower than expected incidences of PONV in this study, the power to conclude any noninferiority of alizapride was reduced to only 41%. " 02/01/1988 - "Alizapride 100 to 200 mg intravenously is efficacious in the prevention of postoperative nausea and vomiting." 02/01/1988 - "Alizapride in prevention of postoperative nausea and vomiting." 01/01/1988 - "However, there was still a significant incidence of 34% of postoperative vomiting in the alizapride group. " 01/01/1988 - "Alizapride in the prevention of postoperative vomiting. "
5.	Pruritus (Itching) 08/01/2003 - "Alizapride reduced the severity of morphine-induced pruritus." 08/01/2003 - "In the metoclopramide group, pruritus was absent in 5 (12%) patients, mild in 23 (55%), moderate in 11 (26%), and severe in 3 (7%), while in the alizapride group, these incidences were, respectively, 5 (12%), 33 (79%), 4 (10%), and 0 (P=0.045, chi(2)-test). " 08/01/2003 - "Just after birth, alizapride-50 mg (alizapride group) or metoclopramide-10 mg (metoclopramide group) were injected i.v. Patients were assessed after surgery for pruritus (absent, mild, moderate or severe) or other untoward symptoms. " 08/01/2003 - "This double-blind study was undertaken to determine whether alizapride inhibits spinal morphine-induced pruritus. " 08/01/2003 - "Effect of intravenous alizapride on spinal morphine-induced pruritus."

Related Drugs and Biologics

1.	Antiemetics
2.	Metoclopramide (Reglan)
3.	Cisplatin (Platino)
4.	Dexamethasone (Maxidex)
5.	Ondansetron (Zofran)
6.	Domperidone (Domperidon)
7.	Droperidol
8.	Cyclophosphamide (Cytoxan)
9.	Morphine (MS Contin)
10.	Benzamides

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Combination Drug Therapy (Combination Chemotherapy)